MEDI 575, identified by its CAS number 1243266-04-7, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential therapeutic applications. It is classified as a small molecule inhibitor, specifically targeting certain pathways involved in disease processes, which may include cancer or autoimmune disorders. The compound's structure typically features specific functional groups that enhance its binding affinity to biological targets, thereby influencing cellular signaling pathways. MEDI 575 is often evaluated in preclinical studies to assess its efficacy, safety, and pharmacokinetic properties. Characteristics such as solubility, stability, and metabolic profile are crucial for determining its suitability for further development. As with many investigational compounds, detailed information regarding its mechanism of action, side effects, and clinical trial results may be limited, as it is still under research. Overall, MEDI 575 represents a promising candidate in the ongoing search for effective therapeutic agents.

MEDI 575

1243266-04-7: MEDI 575, identified by its CAS number 1243266-04-7, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential therapeutic applications. It is classified as a small molecule inhibitor, specifically targeting certain pathways involved in disease processes, which may include cancer or autoimmune disorders. The compound's structure typically features specific functional groups that enhance its binding affinity to biological targets, thereby influencing cellular signaling pathways. MEDI 575 is often evaluated in preclinical studies to assess its efficacy, safety, and pharmacokinetic properties. Characteristics such as solubility, stability, and metabolic profile are crucial for determining its suitability for further development. As with many investigational compounds, detailed information regarding its mechanism of action, side effects, and clinical trial results may be limited, as it is still under research. Overall, MEDI 575 represents a promising candidate in the ongoing search for effective therapeutic agents.

<p>Anti-Human CD140a Monoclonal Antibody</p>

Tovetumab

<p>Tovetumab (MEDI-575) is an anti-PDGFRα mAb inhibiting its signaling, in trials for glioblastoma and NSCLC.</p>

CAS 1243266-04-7

MEDI 575

Tovetumab

Ref: 3D-CLA1336

Tovetumab

Ref: TM-T76764